In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plus Therapeutics Inc.

www.plustherapeutics.com

Latest From Plus Therapeutics Inc.

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Financing StartUps and SMEs

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth

Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.

Financing Business Strategies

Pipeline Watch: Phase III Starts With Rimegepant, ARQ087 And SGX942

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • MacroPore Biosurgery
  • Cytori Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Plus Therapeutics Inc.
  • Senior Management
  • Marc H Hedrick, MD, Pres. & CEO
  • Contact Info
  • Plus Therapeutics Inc.
    Phone: (737) 255-7194
    4200 Marathon Blvd.
    Ste. 200
    Austin, TX 78756
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register